An overview of biosimilars approval in brazil

• At: Seville (Spain) (2022)
• Type: Poster
• Poster code: RSC-008
• By: MACHADO, Fernanda (Federal University of Rio de Janeiro, Brazil)
• Co-author(s): Dr Fernanda Machado, Pharmacist (Federal University of Rio de Janeiro, Macaé, Brazil)
  Dr Flávia Albuquerque (Ministry of Health, Brasília, Brazil)
  Dr Claudia Osorio-de-Castro, National School of Public Health (Oswaldo Cruz Foundation, Rio de Janeiro, Brazil)
  Ms Mariama Falcão (Brazilian Health Regulatory Agency, Brasília, Brazil)
  Mr Gustavo Santos (Brazilian Health Regulatory Agency, Brasília, Brazil)
  Dr Luciane Lopes (Sorocaba University, Sorocaba, Brazil)
  
• Abstract:

  Background information: Brazil has a universal health system that aims to provide care for more than 200 million citizens. Biological medicines consume a significant part of the health budget and the entrance of biosimilars into the market is expected to reduce expenditure and increase access to these therapies. The Brazilian Health Regulatory..

The access to the whole abstract and if available the presentation file is available to FIP members and to congress participants of that specific congress. Please login